Provided by Tiger Trade Technology Pte. Ltd.

Alector Inc.

1.92
+0.11006.08%
Post-market: 1.90-0.0178-0.93%19:58 EDT
Volume:3.97M
Turnover:7.28M
Market Cap:214.38M
PE:-1.77
High:1.92
Open:1.78
Low:1.73
Close:1.81
52wk High:3.40
52wk Low:1.09
Shares:111.66M
Float Shares:84.94M
Volume Ratio:0.19
T/O Rate:4.68%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.0861
EPS(LYR):-1.3900
ROE:-385.11%
ROA:-27.62%
PB:-21.50
PE(LYR):-1.38

Loading ...

Alector to Host Virtual R&D Event on ABC Blood-Brain Barrier Platform and Neurodegeneration Pipeline

Reuters
·
7 hours ago

Mizuho Securities Keeps Their Hold Rating on Alector (ALEC)

TIPRANKS
·
Yesterday

Alector Price Target Raised to $3.00/Share from $2.00 by Morgan Stanley

Dow Jones
·
Yesterday

Analysts Are Bullish on Top Healthcare Stocks: Alector (ALEC), McKesson (MCK)

TIPRANKS
·
Oct 06

NASD Most Active Issues

Dow Jones
·
Oct 06

Analysts Conflicted on These Healthcare Names: Capricor Therapeutics (CAPR), Alector (ALEC) and Irhythm Technologies (IRTC)

TIPRANKS
·
Oct 05

Market Movers | Vaxcyte Soars 47%; Alector Surges 32%; RXO Jumps 24%; Cerebras Rallies 8%; Critical Metals Gains 3%

Tiger Newspress
·
Oct 05

Why is Alector Stock (ALEC) 60% Higher Today?

TIPRANKS
·
Oct 05

Alector Soars as Roche Licenses Parkinson's Therapy for up to $1.27 Billion

Reuters
·
Oct 05

Alector Shares Jump 77.4% to $3.21 Premarket After Roche Inks up to $1.27 Bln Licensing Agreement for Co's Parkinson's Therapy

THOMSON REUTERS
·
Oct 05

Alector Licenses AL050 Program to Roche's Genentech

MT Newswires Live
·
Oct 05

Alector enters exclusive AL050 global licensing agreement with Genentech

TIPRANKS
·
Oct 05

Alector - Retains Ownership of Abc Platform and Full Rights for Pipeline Use

THOMSON REUTERS
·
Oct 05

Alector - Eligible for Tiered Royalties on Net Sales

THOMSON REUTERS
·
Oct 05

Alector - Genentech Responsible for Development, Regulatory, Manufacturing, and Commercialization

THOMSON REUTERS
·
Oct 05

Alector - Partnership Extends Alector's Cash Runway into 2029

THOMSON REUTERS
·
Oct 05

Alector - to Receive $100 Mln Upfront and up to $1.17 Bln in Milestone Payments

THOMSON REUTERS
·
Oct 05

Alector - Grants Genentech Exclusive Global Rights to Develop and Commercialize Al050

THOMSON REUTERS
·
Oct 05

Alector Enters Global License Agreement with Genentech for Brain Penetrant Gcase Enzyme Replacement Therapy for Parkinson’s Disease and Other Neurodegenerative Diseases

THOMSON REUTERS
·
Oct 05

Novartis Halts ALS Drug Development After Mid-Stage Trial Failure

Reuters
·
Sep 17